Drug profile · INN
trabectedin
YONDELIS
trabectedin (YONDELIS) is a dna inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — trabectedin
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
trabectedin (YONDELIS) is a dna inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is trabectedin?
trabectedin (YONDELIS) is a dna inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for trabectedin?
YONDELIS is a marketed brand name for trabectedin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trabectedin?
trabectedin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.